Document Detail

Serum albumin predicts cardiac adverse events in patients with advanced atherosclerosis - interrelation with traditional cardiovascular risk factors.
MedLine Citation:
PMID:  14983239     Owner:  NLM     Status:  MEDLINE    
Low serum albumin is a powerful predictor of cardiovascular adverse events in healthy subjects and patients with subclinical, atherosclerosis. We investigated the association between serum albumin, traditional cardiovascular risk factors, markers of inflammation and cardiovascular outcome in 515 patients with advanced atherosclerosis and severe peripheral artery disease. Cardiovascular risk profile, serum albumin, serum amyloid A (SAA) and fibrinogen were obtained at baseline, and patients were followed for median 21 months (interquartile range 12 to 25) for the occurrence of major adverse cardiac events (MACE: myocardial infarction, percutaneous coronary interventions, coronary artery bypass graft, and death). We observed 135 MACE in 109 patients (21%). Cumulative event-free survival rates at 6, 12, and 24 months were 95%, 91%, and 80%, respectively. Low albumin predicted MACE independently of SAA and fibrinogen. Adjusted hazard ratios for the occurrence of MACE, any death, and the composite of death and MI according to increasing quartiles of albumin were 2.40, 1.14 and 1.09 (p<0.001), 2.94, 1.34 and 1.11 (p=0.003) and 3.63, 1.86 and 1.29 (p<0.001), respectively, as compared to the highest quartile. Considering albumin in conjunction with traditional cardiovascular risk factors (smoking, hyperlipidemia, hypertension and diabetes), we found that low albumin predicted MACE only in patients with a low risk profile (less than 3 risk factors) (p<0.001), whereas low albumin was not associated with MACE in patients with three or more risk factors (p=0.66). We conclude that low serum albumin is associated with cardiovascular outcome of patients with advanced atherosclerosis adding to the prognostic information of other inflammatory markers, and may be particularly useful for risk prediction in patients with few traditional risk factors.
Martin Schillinger; Markus Exner; Wolfgang Mlekusch; Jasmin Amighi; Schila Sabeti; Oliver Schlager; Oswald Wagner; Erich Minar
Related Documents :
19836749 - Serum selenium and prognosis in cardiovascular disease: results from the atherogene study.
16336059 - Efforts to improve subsequent treatment of cardiovascular risk factors in older patient...
8774829 - Variability of ventricular premature complexes and mortality risk.
18187289 - Major events in uremic patients: insight from parameters derived by flow propagation ve...
20467149 - Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis.
20479639 - The effect of chronic kidney disease on fibrin clot properties in patients with acute c...
8470569 - Traumatic laceration of the liver limited to the bare area: ct findings in 25 patients.
3707319 - Peripheral nerve conduction studies and bulbocavernosus reflex in the investigation of ...
23863209 - Prognostic value of eeg in different etiological types of coma.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  91     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-02-25     Completed Date:  2004-10-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  610-8     Citation Subset:  IM    
Department of Angiology, Vienna General Hospital, Medical School, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apolipoproteins / metabolism
Arteriosclerosis / pathology*
Cardiovascular System / metabolism*
Disease-Free Survival
Fibrinogen / metabolism
Follow-Up Studies
Middle Aged
Multivariate Analysis
Myocardial Infarction / diagnosis*,  pathology
Proportional Hazards Models
Prospective Studies
Risk Factors
Serum Albumin / metabolism,  pharmacology*
Serum Amyloid A Protein / metabolism
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Apolipoproteins; 0/Serum Albumin; 0/Serum Amyloid A Protein; 9001-32-5/Fibrinogen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for s...
Next Document:  Epitope mapping of polyclonal clotting factor VIII-inhibitory antibodies using phage display.